Arthritis4Cure was born from more than a decade of academic research that led to a breakthrough innovation in rheumatoid arthritis.

Originating from the Cure-RA Inserm consortium, the company is developing a precision immunology platform targeting the immune drivers of chronic autoimmune inflammation.

With more than €6 million secured through public and private financing, Arthritis4Cure is rapidly advancing toward clinical proof-of-concept in rheumatoid arthritis.